Lyell Immunopharma Inc (LYEL) Stock Price, Quote & News

Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 695 0677

Website: www.lyell.com

Address:

201 Haskins Way, South San Francisco, United States

Hopipaytrader Oct. 22 at 5:07 PM

$LYEL anyone see the overnight -25%

0 · Reply

Hopipaytrader Oct. 22 at 3:25 AM

$LYEL ok deep handle time?

0 · Reply

Hopipaytrader Oct. 17 at 12:28 PM

$LYEL good morning

0 · Reply

fantastex Oct. 17 at 11:20 AM

$LYEL the big pump is yet to come.

0 · Reply

Hopipaytrader Oct. 16 at 12:54 AM

$LYEL beauty

1 · Reply

_CircuitBreaker Oct. 9 at 10:43 PM

Keep a close watch on CMCT! $INAB $OGEN $AGMH $LYEL 1

0 · Reply

fantastex Oct. 6 at 8:03 PM

$LYEL if $SPRB went up 1600% this Company with breakthrough ph2/ph3 phase should go at 200$ overnight! Lol Such

0 · Reply

ObscureCandle Oct. 5 at 11:00 AM

$LYEL Biotech speculation. Pre-revenue stage. Chart shows high risk/reward. No pattern recognition.

1 · Reply

_CircuitBreaker Oct. 3 at 12:44 AM

$LYEL $EKSO $BINI $ARBB -

1 · Reply

Hopipaytrader Oct. 1 at 1:41 PM

$LYEL shinkansen is leaving the station

1 · Reply

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

Sep 2, 2025, 4:05 PM EDT - 7 weeks ago

Lyell Immunopharma Announces Participation in September Investor Conferences

Aug 12, 2025, 4:05 PM EDT - 2 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Jul 25, 2025, 8:00 AM EDT - 3 months ago

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Jul 22, 2025, 9:02 AM EDT - 3 months ago

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement

Jun 23, 2025, 5:00 PM EDT - 4 months ago

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 17, 2025, 6:30 AM EDT - 4 months ago

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Jun 9, 2025, 4:05 PM EDT - 4 months ago

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Jun 4, 2025, 4:05 PM EDT - 5 months ago

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

May 13, 2025, 4:05 PM EDT - 5 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

May 1, 2025, 9:00 AM EDT - 6 months ago

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

$Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma$

Apr 15, 2025, 9:00 AM EDT - 6 months ago

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Mar 11, 2025, 4:05 PM EDT - 8 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Feb 18, 2025, 4:05 PM EST - 8 months ago

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Jan 9, 2025, 9:00 AM EST - 10 months ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Dec 9, 2024, 9:00 PM EST - 11 months ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Nov 5, 2024, 9:30 AM EST - 1 year ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Oct 31, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 25, 2024, 9:24 AM EDT - 1 year ago

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 24, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 24, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

May 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 6, 2024, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Apr 16, 2024, 6:25 PM EDT - 1 year ago

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Mar 5, 2024, 4:30 PM EST - 1 year ago

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Feb 28, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Feb 26, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Announces Participation in March Investor Conferences

Jan 3, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Nov 10, 2023, 2:23 PM EST - 2 years ago

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Nov 9, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Nov 7, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Aug 26, 2023, 9:29 AM EDT - 2 years ago

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

May 4, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

May 2, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

Feb 28, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Jan 3, 2023, 4:05 PM EST - 3 years ago

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

Dec 15, 2022, 7:00 AM EST - 3 years ago

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Dec 1, 2022, 4:05 PM EST - 3 years ago

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

Nov 10, 2022, 4:05 PM EST - 3 years ago

Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series

Nov 8, 2022, 4:05 PM EST - 3 years ago

Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results

Nov 7, 2022, 8:05 AM EST - 3 years ago

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

Oct 6, 2022, 4:05 PM EDT - 3 years ago

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

Hopipaytrader Oct. 22 at 5:07 PM

$LYEL anyone see the overnight -25%

0 · Reply

Hopipaytrader Oct. 22 at 3:25 AM

$LYEL ok deep handle time?

0 · Reply

Hopipaytrader Oct. 17 at 12:28 PM

$LYEL good morning

0 · Reply

fantastex Oct. 17 at 11:20 AM

$LYEL the big pump is yet to come.

0 · Reply

Hopipaytrader Oct. 16 at 12:54 AM

$LYEL beauty

1 · Reply

_CircuitBreaker Oct. 9 at 10:43 PM

Keep a close watch on CMCT! $INAB $OGEN $AGMH $LYEL 1

0 · Reply

fantastex Oct. 6 at 8:03 PM

$LYEL if $SPRB went up 1600% this Company with breakthrough ph2/ph3 phase should go at 200$ overnight! Lol Such

0 · Reply

ObscureCandle Oct. 5 at 11:00 AM

$LYEL Biotech speculation. Pre-revenue stage. Chart shows high risk/reward. No pattern recognition.

1 · Reply

_CircuitBreaker Oct. 3 at 12:44 AM

$LYEL $EKSO $BINI $ARBB -

1 · Reply

Hopipaytrader Oct. 1 at 1:41 PM

$LYEL shinkansen is leaving the station

1 · Reply

ASKING7 Sep. 30 at 8:20 PM

$LYEL nice move recently

0 · Reply

fantastex Sep. 30 at 6:56 PM

$LYEL many sleepers on this. +200/300% move anytime

0 · Reply

Coach757 Sep. 30 at 12:33 PM

$LYEL Is it true Bill Gates took a 5% position in this?

1 · Reply

Hopipaytrader Sep. 25 at 12:40 AM

$LYEL terrible chart ;)

1 · Reply

fantastex Sep. 24 at 2:31 PM

$LYEL 15+ next week.

0 · Reply

Malgo Sep. 23 at 12:12 AM

$LYEL Monthly chart say 33.

0 · Reply

GMExAPE Sep. 17 at 9:22 PM

RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $CATX $FTEK $ANIX $LIVE $LYEL www

0 · Reply

ultistock Sep. 16 at 12:01 AM

$LYEL Merrill is not allowing me to buy or sell LYEL online due to market manipulation risks. Has anyone else experienced this issue?

1 · Reply

None_ Sep. 3 at 9:49 PM

$LYEL $GILD $JNJ $BMY https://www.oncologypipeline.com/apexonco/lyell-needs-beat-breyanzi-and-yescarta

0 · Reply

BioTuesdays Sep. 3 at 3:25 PM

$LYEL initiates Phase 3 CAR T-cell therapy trial in R/R LBCL; forms expert steering committee https://biotuesdays.com/2025/09/03/lyell-initiates-phase-3-car-t-cell-therapy-trial-in-r-r-lbcl-forms-expert-steering-committee/

0 · Reply

fantastex Aug. 20 at 1:21 PM

$LYEL promising pipeline at only 200m market cap with 290m cash + 50m from private placement? Low cash burn around 42m per quarter. Whoever sees good results here will takeover the company 100% for 5/6x current price (55 dollars minimum). Undervalued af.

0 · Reply

Revaluation Aug. 18 at 5:26 PM

$LYEL From the looks of it - stock is not liquid enough to make any large purchases without shooting up the SP. big boys/friends/family wanted in at this discount so they went with a private placement. They didn’t need money, especially raising at this low price… odd

1 · Reply

Market Cap	338.88M
Revenue (ttm)	60,000.00
Net Income (ttm)	-342.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-571,650.00%
Debt to Equity Ratio	0.00

Volume	19,600
Avg Vol	43,884
Day's Range	N/A - N/A
Shares Out	19.21M
Stochastic %K	67%
Beta	-0.07
Analysts	Hold
Price Target	$11.00